Asthma and COPD require different medication regimens. Considering their cost and effectiveness can ensure value for money without compromising care.
In this article…
- How drug treatment of asthma and COPD differs
- Nurses’ roles in prescribing and encouraging adherence
- Why it is vital to choose the right inhaler
Linda Pearce is respiratory consultant nurse, West Suffolk Foundation Trust, and clinical lead, Suffolk COPD Services.
Pearce L (2012) Responsible prescribing for asthma and COPD. Nursing Times; 108: 46, 12-16.
Respiratory medicines are expensive and, for common respiratory conditions, such as asthma and chronic obstructive pulmonary disease (COPD), there are opportunities to make significant savings by optimising their use. Responsible and cost-efficient respiratory prescribing can ensure value for money without compromising the quality of care. Nurses should be aware of the differing regimens recommended for patients with asthma and COPD.
- This article has been double-blind peer reviewed
- Figures and tables can be seen in the attached print-friendly PDF file of the complete article in the ‘Files’ section of this page
5 key points
- Effective use of inhalers will benefit patients and reduce costs
- Inhaled steroids at the lowest appropriate dose should be used for persistent asthma
- Once asthma is under control, consider cautiously stepping down treatment
- COPD patients should receive regular bronchodilator treatment
- Inhaled steroids for COPD should be commenced in moderate/severe disease
According to Asthma UK (2012) 5.4 million people in the UK are receiving treatment for asthma, including 1.1 million children. Alongside this, an estimated 3.2 million people have chronic obstructive pulmonary disease (COPD). Asthma and COPD require long-term management, so medication may be prescribed for many years.
Medication for asthma and COPD is most often delivered by the inhaled route. Nearly £1bn was spent on respiratory inhalers in 2011 by the NHS (NHS Information Centre, 2012). The Department of Health’s Quality, Innovation, Productivity and Prevention programme emphasises the importance of maintaining and improving care while ensuring value for money.
Ensuring a correct diagnosis of asthma or COPD is important, as the management pathways are different. Inhaled cortico-steroids are first-line treatment for persistent asthma symptoms (British Thoracic Society/Scottish Intercollegiate Guidelines Network, 2012), while broncho-dilators are first-line treatment for COPD (National Institute for Health and Clinical Excellence, 2010).
However, non-drug management should not be forgotten. Good lung health includes smoking cessation, pulmonary rehabilitation and good breathing technique.
In primary care, most people with asthma and COPD have (or should have) regular reviews to ensure good disease control. The majority of these reviews are undertaken by a nurse or nurse practitioner, a significant number of whom are non-medical prescribers, or are involved in prescribing decisions.
These nurses are in an ideal position to ensure responsible prescribing, checking the appropriateness of medication and changing or amending it. They also have an important role in checking concordance and adherence (Shepherd, 2011) and regularly assessing the patient’s inhaler technique (Pearce, 2011).
Corticosteroids in persistent asthma
Inhaled corticosteroids reduce airway inflammation, reduce airway hyper-responsiveness and improve airflow, and consequently can both control the disease process and reduce symptoms in asthma.
These drugs are the most effective medication for achieving asthma control but need to be taken regularly. They are the initial treatment of choice for children and adults with persistent asthma symptoms, and are the mainstay for the regular treatment of chronic asthma at step 2 of the BTS/SIGN guideline (BTS/SIGN, 2012).
Regular preventive therapy for asthma, in the form of inhaled corticosteroids, should be started where:
- As-needed short-acting beta2-agonist (relievers) fail to control symptoms - for example, where they are required on a daily basis;
- Symptoms regularly interfere with daily activity or disturb sleep more than once a week;
- The person has had an exacerbation of asthma in the previous two years requiring systemic corticosteroids.
Inhaled corticosteroids differ in potency and bioavailability. In general, 400 micrograms of beclometasone dipropionate (BDP) is equivalent to 400mcg of budesonide or 200mcg of fluticasone, but different CFC-free beclometasone inhalers have different potencies. For example, 400mcg Clenil Modulite is equivalent to 200-300mcg Qvar (MeReC Bulletin, 2012).
A table listing doses of inhaled corticosteroids equivalent to doses of BDP can be found in the BTS/SIGN guideline (page 39); this guideline also recommends that the dose should be appropriate to the severity of disease (BTS/SIGN, 2012).
For example, for adults and children at step 2, it recommends standard dose inhaled corticosteroids (BDP or equivalent) of 200-800mcg/day in adults and 200-400mcg/day in children aged under 12 years.
High-dose inhaled corticosteroids, of 800-2000mcg BDP equivalent/day in adults or 400-800mcg BDP equivalent/day in children aged 5-12 years should only be trialled at step 4. Patients should be maintained at the lowest possible dose of inhaled steroid to minimise adverse effects (MeReC, 2012).
Inhaled corticosteroids in COPD
Corticosteroids are also used in COPD to treat and reduce inflammation in the airways. However, because COPD is a progressive disease, corticosteroids do not produce the dramatic improvements that can be seen when they are used in asthma.
They are used in patients with moderate or severe COPD (forced expiratory volume in one second (FEV1) <50% predicted) who have had two or more exacerbations requiring treatment with antibiotics or oral corticosteroids in a 12-month period (NICE, 2010).
There is no good evidence that inhaled corticosteroids improve survival in people with COPD, or reduce the rate of FEV1 decline, but they may reduce the frequency of COPD exacerbations, and improve quality of life (Burge, 2000).
Local side-effects of inhaled corticosteroids include candidiasis of throat and mouth and/or hoarse voice. Cleaning the teeth and rinsing the mouth after inhalation may reduce these. Correcting inhaler technique and/or adding a spacer device to a metered dose inhaler may reduce oropharyngeal deposition (BTS/SIGN, 2012).
High-dose inhaled corticosteroids may contribute to corticosteroid-induced osteoporosis. They also carry a small risk of glaucoma or cataracts and, if used for prolonged periods, may cause adrenal suppression (Joint Formulary Committee, 2012).
Bronchodilators may be short acting or long acting. beta2-agonists have a direct action on the beta2-receptors, and reduce bronchospasm. They are licensed for both asthma and COPD.
Inhaled short-acting beta2-agonist bronchodilators (SABAs), such as salbutamol and terbutaline, are effective in 5-15 minutes and have a 2-4 hour bronchodilator effect. They are prescribed on an “as needed” basis for mild intermittent asthma at step 1 of the BTS/SIGN guideline (2012) and for relief of breathlessness and exercise limitation in COPD (NICE, 2010).
The inhaled long-acting beta2-agonist bronchodilators (LABAs) salmeterol and formoterol have a 9-12 hour duration of action. Salmeterol has an effect within 30 minutes and formoterol has a faster onset.
In asthma, they are used at step 3 of the BTS/SIGN guideline, as an add-on to inhaled corticosteroid therapy to improve symptom control, and lung function and reduce exacerbations. Long-acting beta2-agonists should be taken twice a day and should not be used for the relief of an acute exacerbation of asthma.
The BTS/SIGN guideline for asthma recommends the addition of a LABA to an inhaled corticosteroid only if regular use of standard-dose inhaled corticosteroids has failed to control asthma adequately, and states that such an addition should be treated as a therapeutic trial. If there is no response to treatment, the LABA should be discontinued. If there has been partial benefit, it should be continued, and the dose of inhaled corticosteroid increased (up to 800mcg/day for adults and adolescents, 400 mcg/day for children aged 5-12 years).
Along with the above LABAs, indacaterol has a licence as monotherapy for COPD (NICE, 2010). As a new product, it is subject to monitoring under the Medicines and Healthcare products Regulatory Agency’s “black triangle” scheme (MHRA, 2012).
Adverse effects of bronchodilators
Side-effects of beta2-agonist bronchodilators are common to both SABAs and LABAs.
The more the patient takes, the more likely are side-effects such as fine tremor, tachycardia, headache and muscle cramp. There is an increased risk of hypokalaemia-induced cardiac arrhythmias with high doses of beta2-agonist bronchodilators.
Although there is no clinical difference between using an inhaled corticosteroid and a LABA in a single or in separate inhalers, combination preparations are recommended for asthma at step 3 and beyond (BTS/SIGN, 2012). A combination LABA/ICS may be appropriate for COPD when an inhaled steroid is required (Burge, 2000).
Combination inhalers may improve adherence as regular therapy will necessitate the use of only one inhaler (Ni Chroinin et al, 2010). Combining can also reduce prescription costs to the patient.
However, reviews of clinical practice have raised questions on the prescribing of inhaled corticosteroids, including whether inappropriately high doses are being prescribed in combination inhalers.
It is important to review the cost of the inhaler/medication combination to prescribe the most appropriate and cost-efficient inhaler (NHS Midlands and East PrescQIPP, 2012). In addition, NICE (2008; 2007) recommends the choice of combination product should be made on an individual basis.
Stepping down in asthma
Regular review of patients is clinically important and stepping down therapy should be considered when good long-term asthma control has been achieved.
Health professionals should focus on stepping down treatment with inhaled corticosteroids and LABAs, where appropriate, to inhaled corticosteroids alone, rather than a cheaper combination inhaler.
For asthma, a reduction in the dose of inhaled steroid should be slow as patients deteriorate at different rates. Reductions should be considered every three months, decreasing the dose by approximately 25-50% each time (BTS/SIGN, 2012).
This may be done by reducing the number of daily doses or by reducing their strength. Again, the most cost-efficient method should be considered. Some children and young adults, with milder asthma and a clear seasonal pattern to their symptoms, may have a more rapid dose reduction during their “good” season.
Anticholinergic drugs for COPD
Muscarinic antagonists (also called anti-cholinergics) block cholinergic receptors and cause the bronchial muscles to relax.
They are licensed for COPD, are not recommended for routine management of asthma, although nebulised short-acting muscarinic antagonists (SAMAs) are recommended to treat acute asthma exacerbations (BTS/SIGN, 2012). The inhaled SAMA ipratropium bromide is effective within 15-30 minutes and has a 4-6 hour bronchodilator effect.
The long-acting muscarinic antagonist (LAMA) tiotropium is licensed for maintenance treatment of COPD, but is not suitable for the relief of acute bronchospasm. It is taken once every 24 hours.
Side-effects of anticholinergic bronchodilators include dry mouth, constipation, headache and nausea.
Triple therapy in the form of LAMA, LABA and inhaled corticosteroids is recommended for more severe COPD. Before triple therapy is started, non-drug management should be optimised (NICE, 2010).
Box 1. Drug delivery systems
With inhaled medication, the choice of delivery device is as important as the choice of drug. Incorrect inhaler technique and non-adherence are two reasons why symptoms become poorly controlled. Nurses have an important role reviewing and correcting technique. Consider the following when prescribing/checking any inhaler device:
- Range of devices and how they work
- Local guidelines and cost-effectiveness
- Respiratory function (ability to inhale at appropriate rate)
- Ability to coordinate actuation of the device and inhalation
- Patient’s experience with inhalers
- Cognitive function and memory
- Ability/disability (for example arthritic hands)
Source: Pearce (2011)
Leukotriene inhibitors (montelukast, zafirlukast) are oral preparations that act by inhibiting one part of the asthmatic inflammatory cascade.
They are licensed for use in both adults and children (can be used in young children as a monotherapy) and are recommended as add-on therapy at step 3 of the BTS/SIGN guidelines where long-acting beta2-agonists have not produced improvement or are unsuitable for other reasons. They should be given as a trial for two months to see if they are effective.
Methylxanthines (theophylline, aminophylline) are used as an add-on therapy for acute or severe chronic asthma at level 4, and are also used in the management of severe COPD (Clinical Knowledge Summaries, 2011a).
Methylxanthines have a narrow therapeutic window above which they are toxic, and below which they are ineffective. They are administered orally or intravenously and regular monitoring is needed.
Systemic corticosteroids may be required to manage deteriorating asthma or COPD exacerbations. For adults with COPD, continuous oral prednisolone 30-50mg daily should be prescribed for 7-14 days.
A single daily dose should be taken in the morning to minimise the disturbance to sleep patterns. Enteric-coated tablets are six times more expensive and there is no firm evidence that they provide more effective gastric protection (Wan, 2010).
Inhaled corticosteroids should be continued, or started, as part of chronic asthma or COPD management, while oral prednisolone is given for the acute phase.
Short courses of oral corticosteroids (less than three weeks) can be stopped abruptly, but gradual withdrawal should be considered for those who have received over three weeks of treatment, or have had repeated courses (CKS, 2011b).
Side-effects of systemic corticosteroids include adrenal suppression, gastrointestinal symptoms such as dyspepsia or peptic ulceration, weight gain, increased appetite, euphoria, thinning of skin, diabetes mellitus and hypertension. However, these should be minimal if they are used within recommended doses for the shortest period necessary.
There is an increased risk of hypokalaemia when corticosteroids are given with methylxanthines, and bone protection therapy such as bisphosphonate should be considered if patients are taking oral corticosteroids for three months or longer (CKS, 2011c).
Although similar drug therapy is used for both asthma and COPD, the introduction of medications varies.
For example, in asthma, the lowest dose of inhaled corticosteroids to maintain control should be prescribed and treatment stepped down once control has been achieved. NICE (2010) recommends that inhaled corticosteroids should be an “add-on” therapy for people with COPD who have two exacerbations of COPD in one year, and high-dose usage is recommended.
ICS and combination ICS/LABA inhalers remain high-cost products and NICE (2008; 2007) recommends that the least costly device that is suitable for the individual should be prescribed.
Keep up to date
Do you want to be kept informed of new articles like this or on a wide range of specialist subjects? If you register with nursingtimes.net you can sign up for regular newsletters on the subjects that interest you, so you don’t miss the news and practice information that’s relevant to you. It’s quick and easy - just click here.
Asthma UK (2012) Facts for Journalists. London: Asthma UK.
Joint Formulary Committee (2012) British National Formulary.
British Thoracic Society/Scottish Intercollegiate Guidelines Network (2012) British Guideline on the Management of Asthma.
Burge PS et al (2000) Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ; 320: 1297-1303.
Clinical Knowledge Summaries (2011a) Theophylline and Aminophylline Monitoring.
Clinical Knowledge Summaries (2011b) Corticosteroids - Oral - Management.
Clinical Knowledge Summaries (2011c) Osteoporosis - Preventing Steroid-Induced - Prescribing Information - Bisphosphonates.
MeReC Bulletin (2012) Implementing key therapeutic topics: 1. NSAIDS; antibiotics; and inhaled corticosteroids in asthma. MeReC Bulletin; 22: 3.
Medicines and Healthcare products Regulatory Agency (2102) Black Triangle List September 2012. London: MHRA
NHS Information Centre (2011) Prescription Costs Analysis 2011. London: NHSIC.
NHS Midlands and East PrescQIPP (2012) Primary Care Prescribing: Inhaled Corticosteroids. tinyurl.com/NHSMids-prescribing
National Institute for Health and Clinical Excellence (2010) Chronic Obstructive Pulmonary Disease (Partial Update). www.nice.org.uk/CG101
National Institute for Health and Clinical Excellence (2008) Inhaled Corticosteroids for the Treatment of Chronic Asthma in Adults and in Children Aged 12 years and over. Technology appraisal 138.
National Institute for Health and Clinical Excellence (2007) Inhaled Corticosteroids for The Treatment of Chronic Asthma in Children Under the Age of 12 Years. Technology appraisal 131.
Ni Chroinin M et al (2010) Addition of inhaled long-acting beta2-agonists to inhaled steroid as first line therapy for persistent asthma in steroid-naïve adults and children. Cochrane Library; Issue 2.
Pearce L (2011) How to teach inhaler technique. Nursing Times; 107: 8, 16-17.
Shepherd M (2011) From compliance to concordance. Nursing Times; 107: 8, 18.
Wan Y (2010) Is there any evidence to support the use of enteric coated (EC) over uncoated prednisolone tablets? National Electronic Library for Medicines.